Updates are available Correction dated 2021-07-13
Click to view Correction: https://doi.org/10.1038/s41572-021-00292-z
-
Authors
Aarsland, Dag https://orcid.org/0000-0001-6314-216X
Batzu, Lucia https://orcid.org/0000-0001-6249-2803
Halliday, Glenda M. https://orcid.org/0000-0003-0422-8398
Geurtsen, Gert J. https://orcid.org/0000-0002-2508-340X
Ballard, Clive https://orcid.org/0000-0003-0022-5632
Ray Chaudhuri, K. https://orcid.org/0000-0003-2815-0505
Weintraub, Daniel
- License Information
-
More Information
Article History
Accepted: 27 May 2021
First Online: 1 July 2021
Change Date: 13 July 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41572-021-00292-z
Competing interests
: This paper represents independent research partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. D.A. has received research support and/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals, Evonik, and GE Health and has served as paid consultant for H. Lundbeck, Eisai, Heptares, Mentis Cura, Eli Lilly, and Biogen. C.B. reports grants and personal fees from Acadia pharmaceutical company, grants and personal fees from Lundbeck, personal fees from Roche, personal fees from Otsuka, personal fees from Biogen, personal fees from Eli Lilly, personal fees from Novo Nordisk, personal fees from AARP, grants and personal fees from Synexus, and personal fees from Exciva outside the submitted work. K.R.C. is in the advisory board of AbbVie, UCB, GKC, Bial, Cynapsus, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Therevance, Scion, Britannia, Acadia and 4D, has received honoraria for lectures from AbbVie, Britannia, UCB, Zambon, Novartis, Boeringer Ingelheim and Bial, and reports grants for investigator-initiated studies from Britania Pharmaceuticals, AbbVie, UCB, GKC and Bial as well as academic grants from EU, IMI EU, Horizon 2020, Parkinson’s UK, NIHR, PDNMG, Kirby Laing Foundation, NPF, MRC, and Wellcome Trust. D.W. has received research funding or support from Michael J. Fox Foundation for Parkinson’s Research, Alzheimer’s Therapeutic Research Initiative (ATRI), Alzheimer’s Disease Cooperative Study (ADCS), the International Parkinson and Movement Disorder Society (IPMDS) and the National Institute on Ageing (NIA), honoraria for consultancy from Acadia, Aptinyx, CHDI Foundation, Clintrex LLC (Alkahest, Aptinyx, Avanir, Otsuka), Eisai, Enterin, Great Lake Neurotechnologies, Janssen, Sage, Scion, Signant Health, Sunovion and Vanda, and license fee payments from the University of Pennsylvania for the QUIP and QUIP-RS. L.B., G.H. and G.G. report no competing interests.
